ClinicalTrials.gg
RecruitingNCT07284459Updated Nov 13, 2026

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of PIPE-791 Dose A and PIPE-791 Dose B in Idiopathic Pulmonary Fibrosis, sponsored by Contineum Therapeutics. Recruiting at 110 sites in 19 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Contineum Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 13, 2026First sites in 6 new countries34 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina — 5 open to participants now, 11 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Argentina.

Planned enrollment
17th of 29
324 · median 340
Started
2026
with 2 others
Phase 2
17 of 29
3 open now
Primary completion
2028-05
later than 6 of 10 live
Registered
27th of 29
by date
Lead sponsor
1 of 29
Contineum Therapeutics

Among the 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina, this one is the 17th largest by planned enrollment, is one of 3 that started in 2026, is one of 17 in phase 2, reaches primary completion later than 6 of the 10 other live ones, and was the 27th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

5 of the 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina, or all of them as a file.
02

Study summary

This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.

Read the detailed description

This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and PK of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis with or without background treatment. The treatment period is 26 weeks and full study duration is up to 36 weeks including Screening and Follow-Up. Approximately 324 participants will be enrolled into one of three treatment arms, PIPE-791 Dose A, PIPE-791 Dose B, or placebo.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic Pulmonary Fibrosis
  • PIPE 791
  • Pulmonary Fibrosis
  • IPF
  • ILD
  • Interstitial lung disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female ≥ 40 years of age at the time of Randomization.
  • A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual interstitial pneumonia (UIP) or probable UIP.
  • Percent predicted (pp) FVC ≥ 40% on Screening spirometry.
  • Participants may enter the study whether or not they are receiving background nintedanib or pirfenidone therapy approved for the treatment of IPF, but not both concurrently.

Key Exclusion Criteria:

  • Those with a history of interstitial lung disease (ILD) other than IPF are not eligible.
  • Those with pulmonary arterial hypertension (PAH) requiring multi-drug therapy are not eligible.
  • Those who have experienced an IPF exacerbation within 6 weeks of Screening, or during Screening, are not eligible.
  • Those with an estimated (eGFR) ≤ 30 ml/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) (Inker 2021) or who have Class B or C hepatic impairment are not eligible.
  • Female participants must not be of .

Additional inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
324 participants (estimated)

Study arms

  • Experimental
    PIPE-791 Dose A

    Drug: PIPE-791 Dose A

  • Experimental
    PIPE-791 Dose B

    Drug: PIPE-791 Dose B

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants will receive a daily oral dose of PIPE-791 in tablet form

    Also known as: PIPE-791

  • Participants will receive a daily oral dose of PIPE-791 in tablet form

    Also known as: PIPE-791

  • DrugPlacebo

    Participants will receive a daily oral dose of matching Placebo in tablet form

06

What researchers measure

Primary outcomes

  1. Absolute change in forced vital capacity (FVC) (mL)

    Time frame: From baseline to Week 26

Secondary outcomes

  1. To investigate the safety and tolerability of PIPE-791 compared to placebo based on percentage of treatment-emergent adverse events (TEAE)

    Time frame: From baseline to Week 30

  2. Relative change in FVC (mL)

    Additional assessment of disease progression through lung function measurements

    Time frame: From baseline to Week 26

  3. Proportion of participants with a ≥10% absolute decline in percent predicted FVC (ppFVC)

    Time frame: From baseline to Weeks 12 and Week 26

  4. Time to first ≥10% absolute decline in ppFVC

    Time frame: From baseline to time of first ≥10% absolute decline, up to Week 26

  5. Absolute change in ppFVC

    Additional assessment of disease progression through lung function measurements

    Time frame: From baseline to Week 26

  6. Relative change in ppFVC

    Additional assessment of disease progression through lung function measurements

    Time frame: From baseline to Week 26

  7. Change in quantitative CT-derived lung fibrosis burden on HRCT

    Additional assessment of disease progression through imaging

    Time frame: From baseline to Week 26

07

Study locations

110 of 110 sites recruiting

Showing the first 100 of 110 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

22 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2028, 28 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 28 months is close to that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Dec 16, 2025
StartActual
Jan 8, 2026
Primary completionEst.
May 2028
CompletionEst.
Jun 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
34 sites added — first sites in Greece, Portugal, Spain, Denmark, Germany and 1 more
All 6 countries

Greece, Portugal, Spain, Denmark, Germany, Belgium

Show 34 added (7 Greece, 6 France, 5 Spain, 4 Taiwan, 3 Poland, 3 Peru, 2 Belgium, 1 Portugal, 1 Australia, 1 Denmark, 1 Germany)
  • General Hospital of Thessaloniki ''G. Papanikolaou'' · Exochi, Greece
  • Centrum Medycyny Oddechowej Mroz sp. j. · Bialystok, Poland
  • ULS de São José, EPE - Hospital de Santa Marta · Lisbon, Portugal
  • Taichung Veterans General Hospital · Taichung, Taiwan
  • Changhua Christian Hospital · Changhua, Taiwan
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  • Clinica Ricardo Palma - PPDS · Lima, Peru
  • Clinica San Pablo Surco · Surco, Peru
  • Alergopneuma Centrum Medyczne - Swidnik · Świdnik, Poland
  • PULMAG s.c. · Sosnowiec, Poland
  • Hospital Clinico Universitario de Valencia · Valencia, Spain
  • University General Hospital - General Hospital of West Attica H Agia Varvara · Chaïdári, Greece
  • University General Hospital of Ioannina · Ioannina, Greece
  • University General Hospital of Alexandroupolis · Alexandroupoli, Greece
  • National Taiwan University Hospital · Taipei, Taiwan
  • PAGNI-University General Hospital of Heraklion · Heraklion, Greece
  • Far Eastern Memorial Hospital · New Taipei City, Taiwan
  • AP-HP - Hopital Avicenne · Bobigny, France
  • Thoracic General Hospital of Athens I SOTIRIA · Athens, Greece
  • CHUS-Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
  • CHU de Rennes - Hôpital Pontchaillou · Rennes, France
  • CHU Amiens Picardie - Site Sud · Amiens, France
  • Hospices Civils de Lyon - Groupement Hospitalier Est · Bron, France
  • Lung Research Qld · Chermside, Australia
  • Hospital Chancay y Servicios Basicos de Salud · Chancay, Peru
  • University General Hospital of Patras · Pátrai, Greece
  • AP-HM - Hôpital Nord · Marseille, France
  • Odense Universitetshospital · Odense C, Denmark
  • Universitätsklinikum Gießen und Marburg GmbH - Standort Gießen · Giessen, Germany
  • Cliniques Universitaires Saint-Luc - PPDS · Brussels, Belgium
  • …and 4 more on the registry record
across 22 updates, Sep 25, 2026 – Nov 13, 2026
Show all 22 updates
  1. Nov 13, 2026
    1 site added
    Show site
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
  2. Nov 10, 2026
    1 site added
    Show site
    • CHU de Nantes - Hôpital Nord Laennec · Nantes, France
  3. Nov 5, 2026
    1 site added
    Show site
    • Hospital Universitario Infanta Leonor · Madrid, Spain
  4. Nov 4, 2026
    1 site added
    Show site
    • CHU UCL Namur - Site Godinne · Yvoir, Belgium
  5. Nov 3, 2026
    1 site added — first site in Belgium
    Show site
    • Cliniques Universitaires Saint-Luc - PPDS · Brussels, Belgium
  6. Nov 2, 2026
    2 sites added — first sites in Denmark and Germany
    Show 2 added (1 Denmark, 1 Germany)
    • Odense Universitetshospital · Odense C, Denmark
    • Universitätsklinikum Gießen und Marburg GmbH - Standort Gießen · Giessen, Germany
  7. Oct 29, 2026
    1 site added
    Show site
    • AP-HM - Hôpital Nord · Marseille, France
  8. Oct 27, 2026
    1 site added
    Show site
    • University General Hospital of Patras · Pátrai, Greece
  9. Oct 26, 2026
    2 sites added
    Show 2 added (1 Australia, 1 Peru)
    • Lung Research Qld · Chermside, Australia
    • Hospital Chancay y Servicios Basicos de Salud · Chancay, Peru
  10. Oct 23, 2026
    2 sites added
    Show 2 added (2 France)
    • CHU Amiens Picardie - Site Sud · Amiens, France
    • Hospices Civils de Lyon - Groupement Hospitalier Est · Bron, France
  11. Oct 22, 2026
    1 site added
    Show site
    • CHU de Rennes - Hôpital Pontchaillou · Rennes, France
  12. Oct 16, 2026
    2 sites added
    Show 2 added (1 Greece, 1 Spain)
    • Thoracic General Hospital of Athens I SOTIRIA · Athens, Greece
    • CHUS-Hospital Clinico Universitario de Santiago · Santiago de Compostela, Spain
  13. Oct 15, 2026
    1 site added
    Show site
    • AP-HP - Hopital Avicenne · Bobigny, France
  14. Oct 14, 2026
    1 site added
    Show site
    • Far Eastern Memorial Hospital · New Taipei City, Taiwan
  15. Oct 9, 2026
    1 site added
    Show site
    • PAGNI-University General Hospital of Heraklion · Heraklion, Greece
  16. Oct 8, 2026
    2 sites added
    Show 2 added (1 Greece, 1 Taiwan)
    • University General Hospital of Alexandroupolis · Alexandroupoli, Greece
    • National Taiwan University Hospital · Taipei, Taiwan
    + 1 other change: verification date
  17. Oct 2, 2026
    2 sites added
    Show 2 added (2 Greece)
    • University General Hospital - General Hospital of West Attica H Agia Varvara · Chaïdári, Greece
    • University General Hospital of Ioannina · Ioannina, Greece
  18. Oct 1, 2026
    5 sites added
    Show 5 added (2 Peru, 2 Poland, 1 Spain)
    • Clinica Ricardo Palma - PPDS · Lima, Peru
    • Clinica San Pablo Surco · Surco, Peru
    • Alergopneuma Centrum Medyczne - Swidnik · Świdnik, Poland
    • PULMAG s.c. · Sosnowiec, Poland
    • Hospital Clinico Universitario de Valencia · Valencia, Spain
  19. Sep 30, 2026
    1 site added — first site in Spain
    Show site
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  20. Sep 29, 2026
    1 site added
    Show site
    • Changhua Christian Hospital · Changhua, Taiwan
  21. Sep 28, 2026
    1 site added
    Show site
    • Taichung Veterans General Hospital · Taichung, Taiwan
  22. Sep 25, 2026
    3 sites added — first sites in Greece and Portugal
    Show 3 added (1 Greece, 1 Poland, 1 Portugal)
    • General Hospital of Thessaloniki ''G. Papanikolaou'' · Exochi, Greece
    • Centrum Medycyny Oddechowej Mroz sp. j. · Bialystok, Poland
    • ULS de São José, EPE - Hospital de Santa Marta · Lisbon, Portugal

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284459
Lead sponsor
Contineum Therapeutics
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Jan 8, 2026
Primary completion
May 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Nikki Nepomuceno
Contact
nnepomuceno@contineum-tx.com
858-333-5280
Marietta Franco
Contact
mfranco@contineum-tx.com
650-450-6634
Mudiaga O Sowho, MD, MPH
study director · Contineum Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PIPE-791

Start the discussion